Eyetech Gains Despite Loss
Shares of Eyetech Pharmaceuticals (EYET) rose Wednesday even though the company late Tuesday said that its third-quarter loss was greater than Wall Street had expected.
However, the real test for Eyetech comes in mid-December when the Food and Drug Administration is expected to rule on its application for Macugen, a drug for the sight-robbing disease called wet age-related macular degeneration, or AMD.
Two hours after markets had closed Tuesday, Eyetech said it lost $24.7 million, or 60 cents a share, on revenue of $13.5 million. The consensus view among analysts polled by Thomson First Call was for a loss of $17.8 million, or 35 cents a share, on revenue of $15.5 million.
For the same period last year, Eyetech lost $14.3 million, or $4.12 a share, on $12.4 million in revenue.In early trading Wednesday, Eyetech's shares climbed 79 cents, or 1.9%, to $41.80. Quarterly financial data is of secondary interest to analysts and investors right now because Eyetech has plenty of financial support from its marketing and development partner Pfizer (PFE). The big issue is when -- and to what extent -- the FDA approves Macugen. An FDA advisory panel reviewed the drug in late August. Although the panel didn't make a recommendation, analysts say they were encouraged by the proceedings and by comments from some committee members. Investors in Eyetech have also been encouraged by competitors' recent setbacks. On Oct. 14, Alcon (ACL) said a key late-stage clinical test showed no difference between its experimental steroid drug called Retaane vs. an existing therapy for wet AMD. Despite the results, Alcon vowed it would submit an application to the FDA by year-end. Eight days later, Iridex (IRIX), a small medical device firm, said preliminary results of its experimental laser treatment for wet AMD showed no significant difference vs. a placebo treatment. Iridex's treatment is called transpupillary thermotherapy, or TTT.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV